Distressed assets Bankruptcy filing and subsequent asset liquidation create a potential window for opportunistic buyers or partners to acquire manufacturing equipment, cGMP assets, and intellectual property related to gene therapy programs, enabling cost-optimized bench and clinical operations.

Asset monetization Recent asset sales to PTC Therapeutics and Surplus Solutions indicate a market for Sangamo’s remaining assets and pipeline components; engage early to evaluate bidding opportunities or strategic collaborations around isaralgagene civaparvovec or associated platforms.

Clinical focus continuity Despite financial distress, current pipeline and ongoing programs related to Fabry disease and gene regulation may attract partners seeking to de-risk investments through co-development, licensing, or milestones tied to ongoing ASGCT activities.

Industry leverage Sangamo’s in vivo genome editing expertise and presentations at ASGCT signal strong scientific credibility; target biotechs and pharma with complementary capabilities in gene therapy manufacturing, regulatory strategy, or distracted supply chains needing outsourcing or tech transfer support.

Cost-efficient collaboration With a disclosed revenue range and substantial funding history, there may be opportunities for service-based partnerships, such as process development, analytical characterization, or equipment lifecycle management, to maximize remaining asset value and accelerate partner programs.